- Home
- H vs BMRN Comparison
H vs BMRN Comparison
Compare H & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- BMRN
- Stock Information
- Founded
- H 1957
- BMRN 1996
- Country
- H United States
- BMRN United States
- Employees
- H N/A
- BMRN N/A
- Industry
- H Hotels/Resorts
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- H Consumer Discretionary
- BMRN Health Care
- Exchange
- H Nasdaq
- BMRN Nasdaq
- Market Cap
- H 12.8B
- BMRN 12.1B
- IPO Year
- H 2009
- BMRN 1999
- Fundamental
- Price
- H $132.92
- BMRN $56.79
- Analyst Decision
- H Buy
- BMRN Buy
- Analyst Count
- H 17
- BMRN 22
- Target Price
- H $149.41
- BMRN $93.43
- AVG Volume (30 Days)
- H 1.1M
- BMRN 2.3M
- Earning Date
- H 05-01-2025
- BMRN 05-01-2025
- Dividend Yield
- H 0.45%
- BMRN N/A
- EPS Growth
- H 23.10
- BMRN 152.82
- EPS
- H 7.89
- BMRN 2.71
- Revenue
- H $3,216,000,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- H $112.35
- BMRN $12.27
- Revenue Next Year
- H $5.56
- BMRN $10.08
- P/E Ratio
- H $16.92
- BMRN $20.99
- Revenue Growth
- H N/A
- BMRN 19.36
- 52 Week Low
- H $102.43
- BMRN $52.93
- 52 Week High
- H $168.20
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- H 60.09
- BMRN 36.74
- Support Level
- H $127.54
- BMRN $57.27
- Resistance Level
- H $133.12
- BMRN $58.59
- Average True Range (ATR)
- H 3.06
- BMRN 1.32
- MACD
- H -0.29
- BMRN -0.03
- Stochastic Oscillator
- H 55.79
- BMRN 16.14
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.